Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT) Short Interest Down 55.4% in August

Posted by Teresa Graham on Aug 29th, 2026

Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT – Get Free Report) was the target of a large decrease in short interest in August. As of August 14th, there was short interest totaling 56,253 shares, a decrease of 55.4% from the July 30th total of 126,080 shares. Based on an average daily trading volume, of 140,397 shares, the short-interest ratio is presently 0.4 days. Approximately 2.5% of the shares of the stock are sold short.

Wall Street Analyst Weigh In

Several research firms recently weighed in on LABT. Wall Street Zen cut shares of Lakewood-Amedex Biotherapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday. Weiss Ratings began coverage on shares of Lakewood-Amedex Biotherapeutics in a report on Monday, July 20th. They set a “sell (e-)” rating for the company. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has an average rating of “Sell”.

Get Our Latest Research Report on LABT

Lakewood-Amedex Biotherapeutics Stock Down 7.6%

Shares of NASDAQ LABT traded down $0.19 during midday trading on Friday, reaching $2.30. 95,736 shares of the stock traded hands, compared to its average volume of 145,485. The company has a market capitalization of $5.45 million and a PE ratio of -0.48. Lakewood-Amedex Biotherapeutics has a one year low of $1.66 and a one year high of $98.20. The stock has a 50 day moving average of $2.54.

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT – Get Free Report) last announced its quarterly earnings results on Friday, August 14th. The company reported ($2.75) earnings per share for the quarter. On average, equities research analysts forecast that Lakewood-Amedex Biotherapeutics will post 2.52 earnings per share for the current fiscal year.

Lakewood-Amedex Biotherapeutics Company Profile

(Get Free Report)

We are a biotechnology company focused on leveraging unique, pioneering science to address unmet needs in the treatment of infectious diseases, improving patient outcomes, and significantly reducing the threat posed by antibiotic-resistant bacterial strains, including methicillin resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococci species (VRE), and others. Antimicrobial resistance (AMR) represents a growing global health crisis, being directly responsible for 1.27 million deaths annually and contributing to nearly 5 million deaths worldwide.